The FDA has approved bemotrizinol as a new over-the-counter sunscreen ingredient, marking the first addition to the agency's approved sunscreen list in nearly two decades. Bemotrizinol has already been widely used in Europe and Asia for years, where regulators determined it safe and effective at blocking both UVA and UVB rays.
The approval addresses a long-standing gap in American sunscreen options. The active ingredients available in U.S. sunscreens have remained largely unchanged since 2006, when avobenzone received approval. Bemotrizinol fills that void with a broad-spectrum filter that works by absorbing ultraviolet radiation across a wide range of wavelengths.
Dermatologists view this development favorably. The ingredient's safety profile underwent rigorous evaluation before FDA clearance, and its established use internationally provided additional reassurance about long-term tolerability. Bemotrizinol differs chemically from commonly used American sunscreen actives like oxybenzone and octinoxate, potentially offering benefits for people with sensitivities to existing formulations.
The approval comes as sunscreen innovation has stalled in the U.S. market compared to global competitors. European and Asian manufacturers have experimented with newer filters, stabilizers, and delivery systems while American companies worked within a restricted ingredient list. This regulatory lag meant Americans had fewer choices for sun protection, even as scientific evidence accumulated supporting other ingredients' safety.
The addition of bemotrizinol does not replace existing sunscreen recommendations. Dermatologists continue advising broad-spectrum SPF 30 or higher daily, reapplication every two hours, and protective clothing for extended sun exposure. The ingredient will likely appear in new formulations over the coming months, giving consumers additional options for effective UV protection.
This approval signals potential movement on other sunscreen ingredients pending FDA review. Several other